Search

Your search keyword '"Kirkegaard, Thomas"' showing total 148 results

Search Constraints

Start Over You searched for: Author "Kirkegaard, Thomas" Remove constraint Author: "Kirkegaard, Thomas"
148 results on '"Kirkegaard, Thomas"'

Search Results

2. Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment

6. Correction to: Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

7. Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

15. Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase

18. Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells

24. Persistent effect of arimoclomol in patients with Niemann-Pick disease type C: 24-month results from an open-label extension of a pivotal phase 2/3 study

26. Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study

27. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology

28. Persistent effect of arimoclomol in patients with Nuemann-Pick disease type C: 12-month results from an open-label extension of a pivotal phase 2/3 study

31. Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study 

32. Cerebrospinal fluid oxidative stress metabolites in patients with bipolar disorder and healthy controls:a longitudinal case-control study

33. Additional file 1: of Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials

35. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase

36. Arimoclomol as a potential therapy for neuronopathic Gaucher Disease

37. Arimoclomol, a clinical candidate for neuronopathic Gaucher disease, increases glucocerebrosidase activity through amplification of heat shock proteins

38. Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder:A naturalistic study

39. Heat shock protein-based therapy for sphingolipidoses

40. Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses

42. Accuracy of abdominal auscultation for bowel obstruction

43. Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium:a prospective cohort study

48. Identification of Autophagosome-associated Proteins and Regulators by Quantitative Proteomic Analysis and Genetic Screens

49. Identification of autophagosome-associated proteins and regulators by quantitative proteomic analysis and genetic screens

50. Activation of phospholipase A2 by Hsp70 in vitro

Catalog

Books, media, physical & digital resources